SUBSCRIBE: Digital / Print / eNewsletter

Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, a turnkey program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease, due to a genetic tendency to over-produce inflammation, and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Interleukin genetics unveils new oral preventative care
Interleukin genetics unveils new oral preventative care
Interleukin genetics introduces the new ILUSTRA system.